Protalix BioTherapeutics, Inc. (PLX) research
Protalix BioTherapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.84
- As of
Protalix BioTherapeutics, Inc. (PLX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-12.
As of . Source: SEC EDGAR filings for PLX. Method and limitations.
Share the PLX intelligence card
See PLX live in the terminal
Track PLX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live PLX terminal, freeActive signals for PLX
- highCONSENSUS_BUY
3 tracked funds increased PLX this 2026Q2, institutional consensus
- highCONSENSUS_BUY
4 tracked funds increased PLX this 2026Q2, institutional consensus
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in PLX
- mediumNEW_POSITION
MILLENNIUM MANAGEMENT LLC new position in PLX
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1111% to PLX (2026Q2)
FREE, NO ACCOUNT
Every signal on PLX, as it fires
You are seeing 5 of 29 signals recorded on PLX since 2026-05-26.
The five above landed across 2 days. The other 24 were recorded on 4 other days. 19 of the 29 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PLX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 74365A309 · 2026Q2 | $2.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 74365A309 · 2026Q2 | $779K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 74365A309 · 2026Q2 | $400K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 74365A309 · 2026Q2 | $99K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 74365A309 · 2026Q2 | $60K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PLX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PLX mentioned in Kresmion daily briefs
PLX against its peers
PLX's operating margin of -10.4% ranks in the 81st percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | PLX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 52.7M USD | 21.0M USD | 69 | 17 |
| Gross margin | n/a | 58.3% | n/a | 5 |
| Operating margin | -10.4% | -279.5% | 81 | 17 |
| Net margin | -12.5% | -202.2% | 69 | 17 |
| Return on equity | -13.7% | -33.3% | 73 | 19 |
Peers (24): KROS, IVVD, NGEN, AVXL, YDES, ADAG, ALEC, ELDN, CGEN, WHWK, CHRS, ALXO, CUE, NAGE, PEPG, NKTX, RNAC, XGN, IPHA, TARA, SRZN, FHTX, ORMP, ACOG. Left out: VRXA (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (PLX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more PLX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PLXand get the insider, 13F, options, and confluence read in one view.